Trial Profile
Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Bladder cancer; Carcinoma; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 24 Aug 2023 Planned End Date changed from 12 Jun 2023 to 12 Jun 2024.
- 24 Aug 2023 Planned primary completion date changed from 12 Jun 2023 to 12 Jun 2024.
- 26 Apr 2023 Planned primary completion date changed from 12 Jun 2022 to 12 Jun 2023.